Cytokinetics Inc at Needham Healthcare Conference (Virtual) Transcript
Hi, good morning. I'm sorry for the slight delay. I'm Serge Belanger, one of the senior healthcare analysts at Needham. I want to welcome you to the 22nd Annual Needham Healthcare Conference. For our next session, we have Cytokinetics. And with us today, we have the CEO, Robert Blum; as well as the Executive VP, R&D, Fady Malik.
So I'll hand it over to Robert to start off, so he can give us an overview of recent developments of the company.
Thank you, Serge, and thank you to Needham for inviting us again to provide an update at this conference. Very pleased to be here and to be able to provide an update on Cytokinetics.
We've had a very, very busy year already, and it's still just the beginning of the second quarter. We've had some very significant positives, as well as, admittedly, some setbacks, but it provides a focus and a concentrated activity for the remainder of this year and peering into next year already.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |